Prophylactic post‐transplant dasatinib administration in a pediatric patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia
Philadelphia chromosome‐positive acute lymphoblastic leukemia has a poor prognosis, even in pediatric patients. Although imatinib‐containing chemotherapy can reportedly improve early event‐free survival, allogeneic hematopoietic stem cell transplantation is still considered to be the main curative t...
Gespeichert in:
| Veröffentlicht in: | Pediatrics international 2013-06, Vol.55 (3), p.e56-e58 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e58 |
|---|---|
| container_issue | 3 |
| container_start_page | e56 |
| container_title | Pediatrics international |
| container_volume | 55 |
| creator | Watanabe, Akihiro Chansu, Shin Ogawa, Atsushi Asami, Keiko Imamura, Masaru |
| description | Philadelphia chromosome‐positive acute lymphoblastic leukemia has a poor prognosis, even in pediatric patients. Although imatinib‐containing chemotherapy can reportedly improve early event‐free survival, allogeneic hematopoietic stem cell transplantation is still considered to be the main curative treatment option. Dasatinib, a novel abl tyrosine kinase inhibitor, is being used for the treatment of relapsed or refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia and is reported to have excellent efficacy. We used dasatinib after bone marrow transplantation prior to the anticipated relapse for the purpose of prophylaxis against relapse. After discontinuation of dasatinib administration, molecular remission has lasted for 7 months. Although preventive use of dasatinib is as yet uncommon, we consider that dasatinib may eradicate the minimal residual disease and prevent recurrence, and it is feasible to administer and appears to be safe. Further studies are needed to confirm our experience in this case. |
| doi_str_mv | 10.1111/ped.12019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492621463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1370633669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4109-436e44c1ac2ecabed41a2d2b9380da02e98f30987aebc5a2808fe5cc768c37273</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhS0EoqWw4AWQJTawSOu_Js4SlfIjVeIuQGIXTZy5iosTB9uhujseAYk35EmYy203SAhvxpr5fEbHh7GnUpxKOmcLDqdSCdneY8fSGFUpIT7fp7tWtrKibo7Yo5yvhRC2seYhO1K6sUpbccx-blJcxl0AV7zjS8zl1_cfJcGclwBz4QNkKH72PYdhopppVnycuZ85cFrsoaT9S-oi8Te-jHwz-gADhmX0wN2Y4hRznJCUaYEv_htycGtBHnbTMsY-QN5vD7h-wcnDY_ZgCyHjk9t6wj69ufx48a66-vD2_cWrq8oZKdrK6BqNcRKcQgc9DkaCGlTfkrEBhMLWbrVobQPYu3NQVtgtnjvX1NbpRjX6hL046C4pfl0xl27y2WEg4xjX3EnTqlpJU-v_o7oRhNV1S-jzv9DruKaZjBBFc2HbRhL18kC5FHNOuO2W5CdIu06Kbh9qR3_b_QmV2Ge3ims_UfeOvEuRgLMDcOMD7v6t1G0uXx8kfwPTzLER</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1369308971</pqid></control><display><type>article</type><title>Prophylactic post‐transplant dasatinib administration in a pediatric patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Watanabe, Akihiro ; Chansu, Shin ; Ogawa, Atsushi ; Asami, Keiko ; Imamura, Masaru</creator><creatorcontrib>Watanabe, Akihiro ; Chansu, Shin ; Ogawa, Atsushi ; Asami, Keiko ; Imamura, Masaru</creatorcontrib><description>Philadelphia chromosome‐positive acute lymphoblastic leukemia has a poor prognosis, even in pediatric patients. Although imatinib‐containing chemotherapy can reportedly improve early event‐free survival, allogeneic hematopoietic stem cell transplantation is still considered to be the main curative treatment option. Dasatinib, a novel abl tyrosine kinase inhibitor, is being used for the treatment of relapsed or refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia and is reported to have excellent efficacy. We used dasatinib after bone marrow transplantation prior to the anticipated relapse for the purpose of prophylaxis against relapse. After discontinuation of dasatinib administration, molecular remission has lasted for 7 months. Although preventive use of dasatinib is as yet uncommon, we consider that dasatinib may eradicate the minimal residual disease and prevent recurrence, and it is feasible to administer and appears to be safe. Further studies are needed to confirm our experience in this case.</description><identifier>ISSN: 1328-8067</identifier><identifier>EISSN: 1442-200X</identifier><identifier>DOI: 10.1111/ped.12019</identifier><identifier>PMID: 23782380</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Bone marrow ; Bone Marrow Purging ; Child ; Clinical outcomes ; Dasatinib ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Humans ; Inhibitor drugs ; Leukemia ; Long-Term Care ; Male ; Pediatrics ; Philadelphia chromosome‐positive acute lymphoblastic leukemia ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; prophylactic ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Secondary Prevention ; Thiazoles - adverse effects ; Thiazoles - therapeutic use ; Transplants & implants</subject><ispartof>Pediatrics international, 2013-06, Vol.55 (3), p.e56-e58</ispartof><rights>2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society</rights><rights>2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society.</rights><rights>Pediatrics International © 2013 Japan Pediatric Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4109-436e44c1ac2ecabed41a2d2b9380da02e98f30987aebc5a2808fe5cc768c37273</citedby><cites>FETCH-LOGICAL-c4109-436e44c1ac2ecabed41a2d2b9380da02e98f30987aebc5a2808fe5cc768c37273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fped.12019$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fped.12019$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23782380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watanabe, Akihiro</creatorcontrib><creatorcontrib>Chansu, Shin</creatorcontrib><creatorcontrib>Ogawa, Atsushi</creatorcontrib><creatorcontrib>Asami, Keiko</creatorcontrib><creatorcontrib>Imamura, Masaru</creatorcontrib><title>Prophylactic post‐transplant dasatinib administration in a pediatric patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia</title><title>Pediatrics international</title><addtitle>Pediatr Int</addtitle><description>Philadelphia chromosome‐positive acute lymphoblastic leukemia has a poor prognosis, even in pediatric patients. Although imatinib‐containing chemotherapy can reportedly improve early event‐free survival, allogeneic hematopoietic stem cell transplantation is still considered to be the main curative treatment option. Dasatinib, a novel abl tyrosine kinase inhibitor, is being used for the treatment of relapsed or refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia and is reported to have excellent efficacy. We used dasatinib after bone marrow transplantation prior to the anticipated relapse for the purpose of prophylaxis against relapse. After discontinuation of dasatinib administration, molecular remission has lasted for 7 months. Although preventive use of dasatinib is as yet uncommon, we consider that dasatinib may eradicate the minimal residual disease and prevent recurrence, and it is feasible to administer and appears to be safe. Further studies are needed to confirm our experience in this case.</description><subject>Bone marrow</subject><subject>Bone Marrow Purging</subject><subject>Child</subject><subject>Clinical outcomes</subject><subject>Dasatinib</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Follow-Up Studies</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Leukemia</subject><subject>Long-Term Care</subject><subject>Male</subject><subject>Pediatrics</subject><subject>Philadelphia chromosome‐positive acute lymphoblastic leukemia</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>prophylactic</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Secondary Prevention</subject><subject>Thiazoles - adverse effects</subject><subject>Thiazoles - therapeutic use</subject><subject>Transplants & implants</subject><issn>1328-8067</issn><issn>1442-200X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1TAQhS0EoqWw4AWQJTawSOu_Js4SlfIjVeIuQGIXTZy5iosTB9uhujseAYk35EmYy203SAhvxpr5fEbHh7GnUpxKOmcLDqdSCdneY8fSGFUpIT7fp7tWtrKibo7Yo5yvhRC2seYhO1K6sUpbccx-blJcxl0AV7zjS8zl1_cfJcGclwBz4QNkKH72PYdhopppVnycuZ85cFrsoaT9S-oi8Te-jHwz-gADhmX0wN2Y4hRznJCUaYEv_htycGtBHnbTMsY-QN5vD7h-wcnDY_ZgCyHjk9t6wj69ufx48a66-vD2_cWrq8oZKdrK6BqNcRKcQgc9DkaCGlTfkrEBhMLWbrVobQPYu3NQVtgtnjvX1NbpRjX6hL046C4pfl0xl27y2WEg4xjX3EnTqlpJU-v_o7oRhNV1S-jzv9DruKaZjBBFc2HbRhL18kC5FHNOuO2W5CdIu06Kbh9qR3_b_QmV2Ge3ims_UfeOvEuRgLMDcOMD7v6t1G0uXx8kfwPTzLER</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Watanabe, Akihiro</creator><creator>Chansu, Shin</creator><creator>Ogawa, Atsushi</creator><creator>Asami, Keiko</creator><creator>Imamura, Masaru</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201306</creationdate><title>Prophylactic post‐transplant dasatinib administration in a pediatric patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia</title><author>Watanabe, Akihiro ; Chansu, Shin ; Ogawa, Atsushi ; Asami, Keiko ; Imamura, Masaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4109-436e44c1ac2ecabed41a2d2b9380da02e98f30987aebc5a2808fe5cc768c37273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Bone marrow</topic><topic>Bone Marrow Purging</topic><topic>Child</topic><topic>Clinical outcomes</topic><topic>Dasatinib</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Follow-Up Studies</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Leukemia</topic><topic>Long-Term Care</topic><topic>Male</topic><topic>Pediatrics</topic><topic>Philadelphia chromosome‐positive acute lymphoblastic leukemia</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>prophylactic</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Secondary Prevention</topic><topic>Thiazoles - adverse effects</topic><topic>Thiazoles - therapeutic use</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watanabe, Akihiro</creatorcontrib><creatorcontrib>Chansu, Shin</creatorcontrib><creatorcontrib>Ogawa, Atsushi</creatorcontrib><creatorcontrib>Asami, Keiko</creatorcontrib><creatorcontrib>Imamura, Masaru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Pediatrics international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watanabe, Akihiro</au><au>Chansu, Shin</au><au>Ogawa, Atsushi</au><au>Asami, Keiko</au><au>Imamura, Masaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prophylactic post‐transplant dasatinib administration in a pediatric patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia</atitle><jtitle>Pediatrics international</jtitle><addtitle>Pediatr Int</addtitle><date>2013-06</date><risdate>2013</risdate><volume>55</volume><issue>3</issue><spage>e56</spage><epage>e58</epage><pages>e56-e58</pages><issn>1328-8067</issn><eissn>1442-200X</eissn><abstract>Philadelphia chromosome‐positive acute lymphoblastic leukemia has a poor prognosis, even in pediatric patients. Although imatinib‐containing chemotherapy can reportedly improve early event‐free survival, allogeneic hematopoietic stem cell transplantation is still considered to be the main curative treatment option. Dasatinib, a novel abl tyrosine kinase inhibitor, is being used for the treatment of relapsed or refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia and is reported to have excellent efficacy. We used dasatinib after bone marrow transplantation prior to the anticipated relapse for the purpose of prophylaxis against relapse. After discontinuation of dasatinib administration, molecular remission has lasted for 7 months. Although preventive use of dasatinib is as yet uncommon, we consider that dasatinib may eradicate the minimal residual disease and prevent recurrence, and it is feasible to administer and appears to be safe. Further studies are needed to confirm our experience in this case.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>23782380</pmid><doi>10.1111/ped.12019</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1328-8067 |
| ispartof | Pediatrics international, 2013-06, Vol.55 (3), p.e56-e58 |
| issn | 1328-8067 1442-200X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1492621463 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Bone marrow Bone Marrow Purging Child Clinical outcomes Dasatinib Dose-Response Relationship, Drug Drug Administration Schedule Follow-Up Studies Hematopoietic Stem Cell Transplantation Humans Inhibitor drugs Leukemia Long-Term Care Male Pediatrics Philadelphia chromosome‐positive acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy prophylactic Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Secondary Prevention Thiazoles - adverse effects Thiazoles - therapeutic use Transplants & implants |
| title | Prophylactic post‐transplant dasatinib administration in a pediatric patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A53%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prophylactic%20post%E2%80%90transplant%20dasatinib%20administration%20in%20a%20pediatric%20patient%20with%20Philadelphia%20chromosome%E2%80%90positive%20acute%20lymphoblastic%20leukemia&rft.jtitle=Pediatrics%20international&rft.au=Watanabe,%20Akihiro&rft.date=2013-06&rft.volume=55&rft.issue=3&rft.spage=e56&rft.epage=e58&rft.pages=e56-e58&rft.issn=1328-8067&rft.eissn=1442-200X&rft_id=info:doi/10.1111/ped.12019&rft_dat=%3Cproquest_cross%3E1370633669%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1369308971&rft_id=info:pmid/23782380&rfr_iscdi=true |